Kyntra Bio
KYNB
134 hedge funds and large institutions have $699M invested in Kyntra Bio in 2016 Q1 according to their latest regulatory filings, with 24 funds opening new positions, 53 increasing their positions, 35 reducing their positions, and 24 closing their positions.
51% more repeat investments, than reductions
Existing positions increased: 53 | Existing positions reduced: 35
18% more call options, than puts
Call options by funds: $4.92M | Put options by funds: $4.18M
0% more funds holding
Funds holding: 134 → 134 (0)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
0% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 24
27% less capital invested
Capital invested by funds: $963M → $699M (-$264M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$8.16M |
| 2 |
O
OppenheimerFunds
New York
|
+$7.04M |
| 3 |
PC
PointState Capital
New York
|
+$6.98M |
| 4 |
VAM
Visium Asset Management
New York
|
+$6.61M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$5.85M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$9.46M |
| 2 |
HCMT
Highland Capital Management (Texas)
Dallas,
Texas
|
-$7.32M |
| 3 |
EC
EcoR1 Capital
San Francisco,
California
|
-$7.03M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
-$5.98M |
| 5 |
CCI
Columbus Circle Investors
|
-$4.33M |
KYNB Hedge Fund Activity: Q1 2016 in Review
134 of the 3,765 institutional investors tracked by Wall St. Rank reported a position in Kyntra Bio (KYNB) for Q1 2016, worth a combined $699M — down 27% from $963M a quarter earlier.
Fund positioning in KYNB was balanced in Q1 2016: 24 funds opened new positions, 24 closed out, 53 added to existing stakes and 35 trimmed.
The largest buyer was Goldman Sachs, adding an estimated $8.16M. The largest seller was JP Morgan Chase, cutting an estimated $9.46M.
- 134 institutional investors held Kyntra Bio (KYNB) as of Q1 2016, unchanged from Q4 2015.
- Funds reported $699M of Kyntra Bio stock for Q1 2016, down 27% quarter-over-quarter.
- 24 funds opened new Kyntra Bio positions in Q1 2016 and 24 closed out, a net change of 0 holders.
- The largest Kyntra Bio buyer in Q1 2016 was Goldman Sachs, an estimated $8.16M added.
- The largest Kyntra Bio seller in Q1 2016 was JP Morgan Chase, an estimated $9.46M sold.
Based on aggregated 13F filings for Q1 2016.